Search
News & Events
World-first trial to seek child-specific treatments for dangerous bloodstream infectionsThe Kids Research Institute Australia, Perth Children’s Hospital (PCH) and the Peter Doherty Institute for Infection and Immunity (Doherty Institute) will spearhead the paediatric arm of a world-first global platform trial designed to uncover treatments for Staphylococcus aureus bloodstream infection.
News & Events
Worried about your child getting coronavirus? Here’s what you need to knowComparatively few children have tested positive for coronavirus (COVID-19). Here’s what we know so far about how children are affected.
News & Events
Shot in the arm for Strep A vaccine bidThe Leducq Foundation has bolstered an Australian-led bid to develop a Strep A vaccine, committing USD4.3 million to fund critical scientific work.
Research
Determinants of attenuation in the envelope protein of the flavivirus AlfuyMurray Valley encephalitis virus (MVEV) is a mosquito-borne flavivirus endemic to Australia and Papua New Guinea.
Research
Nasopharyngeal carriage of Streptococcus pneumoniae: prevalence and risk factors in HIV-positive children in TanzaniaPneumococcal colonization of the nasopharynx is especially common in young children and is a pre-requisite for pneumococcal disease...
Research
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 yearsWe present further data on vaccine efficacy (VE) against HPV-16/18 in the total vaccinated cohort including women who may have been exposed to HPV-16/18...
Research
Is Streptococcus pyogenes resistant or susceptible to trimethoprim- sulfamethoxazole?Streptococcus pyogenes is commonly believed to be resistant to trimethoprim-sulfamethoxazole (SXT), resulting in reservations about using SXT for skin and...
Research
The microbiology of impetigo in Indigenous childrenPrevalence and antimicrobial resistance of impetigo pathogens in a randomised, controlled trial of impetigo treatment conducted in remote Indigenous communities
Research
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World PerspectiveThis review supports the recommended use of palivizumab for reducing RSV-associated hospitalisation rates in premature babies born at gestational age <33 weeks.